(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of 160% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Verona Pharma's revenue in 2025 is $42,279,000.On average, 5 Wall Street analysts forecast VRNA's revenue for 2025 to be $198,676,544,207, with the lowest VRNA revenue forecast at $180,155,227,190, and the highest VRNA revenue forecast at $246,418,359,244. On average, 5 Wall Street analysts forecast VRNA's revenue for 2026 to be $387,549,924,731, with the lowest VRNA revenue forecast at $319,615,767,966, and the highest VRNA revenue forecast at $529,425,225,383.
In 2027, VRNA is forecast to generate $481,442,750,156 in revenue, with the lowest revenue forecast at $450,184,118,661 and the highest revenue forecast at $518,262,399,608.